Contract facts
FederalNo full NAICS 424210 intel page yet. Browse NAICS intelligence
4571140646!VYVGART 400 MG/20 ML VIAL 20ML is a federal award for Dla Troop Support held by Amerisourcebergen Drug Corp. Estimated value $109K ($109K obligated). Current period of performance ends Apr 2, 2026. Place of performance: CONSHOHOCKEN PA.
4571140646!VYVGART 400 MG/20 ML VIAL 20ML
Recompete timing
PublicCurrent PoP ended Apr 2, 2026 (141 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.
Incumbent footprint
Public recordAmerisourcebergen Drug Corp — $19.3B obligated across 1,357,999 awards (firm-wide, all agencies) · lead buyer Department of Defense (DOD).
Related awards
Same parent · incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract SPE2DR26FG5QQ?
SPE2DR26FG5QQ (4571140646!vyvgart 400 MG 20 ML VIAL 20ml) is a Dla Troop Support award with a potential value of $109K, currently held by Amerisourcebergen Drug Corp. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded SPE2DR26FG5QQ?
Dla Troop Support awarded SPE2DR26FG5QQ to Amerisourcebergen Drug Corp (potential $109K).
Who is the incumbent on SPE2DR26FG5QQ?
Amerisourcebergen Drug Corp is the incumbent with $19.3B across 1357999 related awards in SCOUT’s public footprint. The current period of performance ends Apr 2, 2026.
When does Amerisourcebergen Drug Corp’s SPE2DR26FG5QQ come up for recompete?
SCOUT tracks a period-of-performance end of Apr 2, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.
